Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial

BACKGROUND: Aponermin, a circularly permuted tumor necrosis factor-related apoptosis-inducing ligand, is a potential death receptor 4/5-targeted antitumour candidate. Previous phase 1/2 studies have demonstrated the efficacy of aponermin in patients with relapsed or refractory multiple myeloma (RRMM...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Zhongjun, Leng, Yun, Fang, Baijun, Liang, Yang, Li, Wei, Fu, Chengcheng, Yang, Linhua, Ke, Xiaoyan, Jiang, Hua, Weng, Jianyu, Liu, Li, Zhao, Yaozhong, Zhang, Xuejun, Huang, Zhongxia, Liu, Aichun, Shi, Qingzhi, Gao, Yuhuan, Chen, Xiequn, Pan, Ling, Cai, Zhen, Wang, Zhao, Wang, Yafei, Fan, Yaqun, Hou, Ming, Ma, Yigai, Hu, Jianda, Liu, Jing, Zhou, Jianfeng, Zhang, Xiaohong, Meng, Haitao, Lu, Xuzhang, Li, Fei, Ren, Hanyun, Huang, Bintao, Shao, Zonghong, Zhou, Hebing, Hu, Yu, Yang, Shifang, Zheng, Xiangjun, Wei, Peng, Pang, Hongyan, Yu, Wei, Liu, Yuzhang, Gao, Sujun, Yan, Lingzhi, Ma, Yanping, Jing, Hongmei, Du, Juan, Ling, Wei, Zhang, Jingyi, Sui, Weiwei, Wang, Fuxu, Li, Xin, Chen, Wenming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576321/
https://www.ncbi.nlm.nih.gov/pubmed/37838670
http://dx.doi.org/10.1186/s12885-023-11489-8

Ejemplares similares

Ejemplares similares